Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Companyâs pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļFATE
āļāļ·āđāļāļāļĢāļīāļĐāļąāļFate Therapeutics Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 01, 2013
āļāļĩāļāļĩāđāļValamehr (Bahram)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ181
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļOct 01
āļāļĩāđāļāļĒāļđāđ12278 Scripps Summit Drive
āđāļĄāļ·āļāļSAN DIEGO
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ92131
āđāļāļĢāļĻāļąāļāļāđ18588751803
āđāļ§āđāļāđāļāļāđhttps://fatetherapeutics.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļFATE
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 01, 2013
āļāļĩāļāļĩāđāļValamehr (Bahram)
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Dr. Karin Jooss, Ph.D.
Independent Director
Dr. Yuan Xu, Ph.D.
Independent Director
Mr. Michael Lee
Independent Director
Mr. Matthew C. Abernethy, CPA
Mr. Matthew C. Abernethy, CPA
Independent Director
Mr. Kamal Adawi
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Dr. Karin Jooss, Ph.D.
Independent Director